Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Change in Acquisitions & Divestments (2016 - 2023)

Rein Therapeutics (RNTX) has disclosed Change in Acquisitions & Divestments for 8 consecutive years, with $500000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 95.83% to $500000.0 in Q3 2023 year-over-year; TTM through Jun 2024 was $500000.0, a 98.55% decrease, with the full-year FY2023 number at $16.2 million, down 66.36% from a year prior.
  • Change in Acquisitions & Divestments was $500000.0 for Q3 2023 at Rein Therapeutics, down from $8.5 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $23.8 million in Q3 2021 to a low of $500000.0 in Q3 2023.
  • A 5-year average of $7.5 million and a median of $7.0 million in 2019 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: skyrocketed 1257.2% in 2021, then crashed 95.83% in 2023.
  • Rein Therapeutics' Change in Acquisitions & Divestments stood at $7.5 million in 2019, then tumbled by 80.02% to $1.5 million in 2020, then soared by 233.33% to $5.0 million in 2021, then skyrocketed by 34.04% to $6.7 million in 2022, then tumbled by 92.54% to $500000.0 in 2023.
  • Per Business Quant, the three most recent readings for RNTX's Change in Acquisitions & Divestments are $500000.0 (Q3 2023), $8.5 million (Q2 2023), and $7.2 million (Q1 2023).